Cellectar Biosciences

Cellectar Biosciences is a clinical-stage biopharmaceutical company. It focuses on the discovery, development, and commercialization of cancer therapeutics. The company's core objective is to leverage its proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that specifically target cancer cells, offering higher efficacy and better safety with fewer off-target effects. Its lead PDC therapeutic, iopofosine, is a small-molecule PDC designed to deliver iodine-131 directly to cancer cells while limiting exposure to healthy cells.